Propanc Biopharma Shares Rally 200% After $5M Buyback and Reverse Split
PPCB•Propanc Biopharma authorized a $5 million common stock repurchase program after implementing a 1-for-25 reverse split on May 18, reducing its outstanding shares from 57 million to 2.3 million. The microcap biotech’s shares jumped over 200% as management cited undervaluation and outlined ongoing Phase 1b cancer research collaborations.
1. $5M Share Repurchase Program
Propanc Biopharma’s board approved a share repurchase program authorizing up to $5 million to buy back common stock. Management stated repurchases will occur when market price meaningfully understates intrinsic value and when buybacks compete favorably with other uses of capital.
2. Reverse Stock Split Impact
On May 18, Propanc implemented a 1-for-25 reverse stock split, cutting its share count from approximately 57 million to about 2.3 million outstanding shares. This move was designed to meet Nasdaq’s $1 minimum bid price requirement and support future growth.
3. Cancer Research Pipeline
The company is advancing two cancer programs, including a Phase 1b first-in-human study with a pharmacokinetics assay developed in partnership with FyoniBio. It also maintains a multi-year research collaboration with Spanish universities to evaluate an anti-aging compound and support fibrosis- and cancer-related patent applications.
4. Stock Surge and Market Reaction
Following the buyback announcement and reverse split, Propanc shares soared over 200%, driving market capitalization to around $4 million. Retail investor sentiment turned extremely bullish alongside high trading volumes, though some view the rally as a short-term momentum play.
